Valinor Secures $13 Million Seed Funding to Advance AI-Driven Patient Selection Platform for Clinical Trials
核心洞察
Valinor (搜索) raised $13 million in seed funding led by CRV (搜索) to scale its multimodal machine learning platform for predicting patient response to therapies.
The company's AI models are trained on proprietary matched datasets of patient-derived multi-omic samples and treatment outcomes to distinguish responders from non-responders.
The platform aims to improve clinical trial success rates, reduce R&D costs, and accelerate delivery of life-saving medicines to patients.
San Francisco-based artificial intelligence company Valinor (搜索) has secured $13 million in seed funding to advance its proprietary machine learning platform designed to improve clinical trial outcomes through enhanced patient selection. The financing round was led by CRV (搜索), with participation from Harpoon Ventures (搜索), Amino Collective (搜索), and Pelion Venture Partners (搜索), alongside notable angel investors including Charlie Songhurst, Surya Midha, Axel Ericsson, and Kyle Harrison.
Multimodal AI Platform for Patient Response Prediction
Valinor (搜索)'s platform represents a novel approach to addressing one of the pharmaceutical industry's most persistent challenges: identifying patients most likely to respond to experimental therapies. The company's models are trained on matched datasets of patient-derived multi-omic samples and treatment outcomes, enabling the first multimodal machine learning models capable of predicting patient response across disease indications.
"Our models are built to surface meaningful features that underlie patient response," said Joshua Pacini, Founder and Chief Executive Officer of Valinor (搜索). "We believe this approach will empower our pharmaceutical partners to improve clinical trial success rates, cut R&D costs and, most importantly, speed the delivery of life-saving medicines to patients."
The proprietary platform enables drug developers to distinguish responders from non-responders while surfacing novel biology associated with response. This capability can reframe target patient populations and uncover potential new indications based on real-world patient data, addressing critical inefficiencies in traditional clinical trial design.
Strategic Investment in AI-Driven Drug Development
The funding reflects growing investor confidence in AI-powered approaches to de-risk drug development. Brittany Walker, General Partner at CRV (搜索), highlighted the company's unique positioning in the competitive landscape: "As early backers of tech bio pioneers like Recursion, we've seen AI become the driving force accelerating the next generation of drug development. Valinor (搜索) pushes the frontier further with an AI-first, disease-focused platform training on exceptional clinical data. We believe this approach can meaningfully improve clinical trial success."
Expansion Plans and Platform Development
With the new capital, Valinor (搜索) plans to accelerate expansion of its proprietary matched omics and clinical outcome datasets while advancing AI models that support more data-driven decision-making in drug development. The company will also grow its San Francisco-based team, with particular focus on recruiting additional top-tier machine learning talent.
Pacini emphasized the funding's role in scaling the platform: "With this funding, we are accelerating the expansion of our proprietary matched omics and clinical outcome datasets and advancing our AI models that allow our pharma partners to make smarter, data-driven decisions in drug development."
The company operates at the intersection of artificial intelligence and therapeutic research, positioning itself among a growing group of technology-driven biotech companies using advanced analytics to improve drug development efficiency. By developing a suite of patient-derived datasets and predictive models, Valinor (搜索) seeks to support pharmaceutical companies across therapeutic areas and drug modalities, ultimately improving the probability of success for experimental therapies and accelerating progress in therapeutic research.